Current regimens and novel agents for mantle cell lymphoma (Q38224186)

31 August 2017

Current regimens and novel agents for mantle cell lymphoma (English)

1 reference

31 August 2017

Yiming Chen

1

1 reference

31 August 2017

Michael Wang

series ordinal

2

1 reference

31 August 2017

Jorge Romaguera

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

28 June 2014

1 reference

British Journal of Haematology

31 August 2017

1 reference

31 August 2017

167

1 reference

31 August 2017

1

1 reference

31 August 2017

3-18

1 reference

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

31 August 2017

1 reference

Lenalidomide--the phoenix rises.

21 January 2018

1 reference

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

21 January 2018

1 reference

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

21 January 2018

1 reference

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

21 January 2018

1 reference

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial [...]

21 January 2018

1 reference

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

21 January 2018

1 reference

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

21 January 2018

1 reference

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation

21 January 2018

1 reference

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

21 January 2018

1 reference

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

21 January 2018

1 reference

Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

21 January 2018

1 reference

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

21 January 2018

1 reference

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

21 January 2018

1 reference

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

21 January 2018

1 reference

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

21 January 2018

1 reference

Indolent mantle cell lymphoma

21 January 2018

1 reference

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

21 January 2018

1 reference

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

21 January 2018

1 reference

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

21 January 2018

1 reference

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

21 January 2018

1 reference

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Targeting Bruton's tyrosine kinase in B cell malignancies

21 January 2018

1 reference

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age.

21 January 2018

1 reference

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma.

21 January 2018

1 reference

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

21 January 2018

1 reference

Molecular pathogenesis of mantle cell lymphoma

21 January 2018

1 reference

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

21 January 2018

1 reference

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

21 January 2018

1 reference

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

21 January 2018

1 reference

Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

21 January 2018

1 reference

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 January 2018

1 reference

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

21 January 2018

1 reference

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

21 January 2018

1 reference

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

21 January 2018

1 reference

Is there a role for "watch and wait" in patients with mantle cell lymphoma?

21 January 2018

1 reference

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

21 January 2018

1 reference

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

21 January 2018

1 reference

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

21 January 2018

1 reference

Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis

21 January 2018

1 reference

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

21 January 2018

1 reference

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

21 January 2018

1 reference

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

21 January 2018

1 reference

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.

21 January 2018

1 reference

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

21 January 2018

1 reference

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma

21 January 2018

1 reference

Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome

21 January 2018

1 reference

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature

21 January 2018

1 reference

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes

21 January 2018

1 reference

Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499

21 January 2018

1 reference

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

21 January 2018

1 reference

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation

21 January 2018

1 reference

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study

21 January 2018

1 reference

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

21 January 2018

1 reference

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

21 January 2018

1 reference

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers

21 January 2018

1 reference

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

21 January 2018

1 reference

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

21 January 2018

1 reference

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

21 January 2018

1 reference

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13000

1 reference

31 August 2017

1 reference